ArticleOncology letters2026
Astragaloside IV suppresses triple-negative breast cancer cell migration and invasion by targeting BCAT1-mediated branched-chain amino acid metabolism.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Branched-chain amino acid (BCAA) transaminase 1 (BCAT1), the rate-limiting enzyme in BCAA metabolism, serves a pivotal role in tumor progression. Astragaloside IV (AS-IV) exhibits potential antitumor properties; however, whether AS-IV suppresses breast cancer migration by modulating BCAA metabolism via BCAT1 remains to be elucidated. The present study aimed to investigate whether AS-IV inhibits the invasion and migration of MDA-MB-231 triple-negative breast cancer (TNBC) cells by targeting BCAT1-mediated BCAA metabolic reprogramming. The present study used network pharmacology to predict AS-IV targets against breast cancer invasion, followed by BCAT1 knockdown and overexpression in MDA-MB-231 cells. Using molecular docking, cellular thermal shift assay, wound healing, Transwell, western blotting, quantitative PCR and liquid chromatography-mass spectrometry metabolomics, the present study systematically evaluated: i) AS-IV-BCAT1 direct binding and protein stability; ii) BCAA metabolic flux regulation via the branched-chain α-ketoacid dehydrogenase kinase (BCKDK)/branched-chain α-ketoacid dehydrogenase (BCKDH) axis; and iii) functional impacts on breast cancer cell migration and invasion. Network pharmacology predicted BCAT1 as a key potential target of AS-IV, with significant enrichment of the BCAA metabolic pathway. The results of the present study suggested that AS-IV binds to and stabilizes BCAT1
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.